Skip to main content

Table 1 Clinical data of patients enrolled in this study

From: Topical ropivacaine for analgesia of aplasia cutis congenita in newborns with hereditary epidermolysis bullosa

Patient Age Birth weight Term EB type ACC Background therapy Premedication before care Ropivacaine 2 mg/ml quantity per day/ duration Non pharma-cological analgesic Apnea during care
1 5.5 y 3000 g 41w AR dystrophic EB, severe 2 feet Paracetamol, morphine, ketamine, amitriptyline Morphine, ketamine, NO 0.5 to 1 mg/4 y Sucrose
2 4.5 y 2530 g 38w Junctional intermediate 2 feet, 2 wrists Paracetamol, morphine Morphine, ketamine 0.5 mg/30 d Sucrose Yes
3 4.5 y 3400 g 38w AD EB, simplex severe left ankle Paracetamol, amitriptyline Morphine 0.05 mg/31 d Sucrose
4 20 m 3380 g 38w AD EB simplex, severe 2 legs Paracetamol, morphine, ketamine, then sedated condition then paracetamol, morphine, midazolam, amitriptyline, chlorpromazine Morphine, ketamine, NO then morphine, chlorpromazine 0.2 mg/30 d Sucrose Yes
5 13 m 3150 g 40w AD EB simplex, severe 2 ankles Paracetamol Morphine, ketamine, amitriptyline 0.2 mg/45 d Sucrose
6 9 m 3170 g 37w Junctional intermediate 2 knees, feet, forearms and hands Paracetamol, morphine Morphine, ketamine 0.8 mg/14 d Sucrose
7 8 m 2680 g 37w AD EB simplex, severe 2 legs Paracetamol, morphine, ketamine, Morphine, ketamine, midazolam 0.2 mg/10 d Sucrose
8 6 m 3000 g 39w AR dystrophic EB, severe 2 feet Paracetamol Morphine 0.4 mg/10 d Sucrose
  1. EB Epidermolysis bullosa, ACC aplasia cutis congenita, AD autosomal dominant, AR autosomal recessive, NO nitrous oxide